Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

727
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
727
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

3.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
3.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.

Haematologica·2026
Same author

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Blood·2026
Same author

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

HemaSphere·2026
Same author

Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party.

HemaSphere·2026
Same author

Strategies for Managing Toxicities With High-Dose Methotrexate in Haematological Malignancies: Lessons From Clinical Cases.

Clinical case reports·2026

Related Experiment Video

Updated: Aug 18, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

CNS prophylaxis in aggressive B-cell lymphoma.

Matthew R Wilson1, Sabela Bobillo2, Kate Cwynarski3

  • 1Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.

Hematology. American Society of Hematology. Education Program
|December 9, 2022
PubMed
Summary

Preventing central nervous system relapse in diffuse large B-cell lymphoma (DLBCL) is challenging. New molecular diagnostics may improve risk identification and guide more effective CNS prophylaxis strategies.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K

Related Experiment Videos

Last Updated: Aug 18, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K

Area of Science:

  • Hematology
  • Oncology
  • Neurology

Background:

  • Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) significantly impacts patient outcomes.
  • Historically poor prognoses for secondary CNS lymphoma (SCNSL) are being challenged by intensive therapies.
  • Current CNS prophylaxis methods lack specificity, and the efficacy of interventions like high-dose methotrexate (HD-MTX) is debated.

Approach:

  • Reviewing recent evidence (last 5 years) on CNS relapse prevention in DLBCL.
  • Evaluating molecular diagnostics for improved identification of high-risk patients.
  • Analyzing data questioning the efficacy of HD-MTX and exploring novel therapies.

Key Points:

  • Molecular diagnostics offer potential for more precise identification of patients at high risk for CNS relapse.
  • Evidence suggests limitations in the efficacy of current prophylactic strategies, including HD-MTX.
  • Management of SCNSL requires re-evaluation in light of new data and therapeutic advancements.

Conclusions:

  • There is an urgent need for improved methods to identify patients at high risk of CNS relapse in DLBCL.
  • Further research into novel prophylactic interventions with greater efficacy and reduced toxicity is warranted.
  • A refined approach, potentially incorporating molecular markers, is needed for managing CNS involvement in DLBCL.